Philogen Archives | Be Korea-savvy

Home / Posts tagged Philogen

Nidlegy™ Phase III PIVOTAL Trial Meets the Study’s Primary Objective Demonstrating Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival for Patients with Locally Advanced Fully Resectable Melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase [...]

Philogen Provides Corporate Update

211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy™ treatment of Stage IIIB/C melanoma, in line with expectations. Fibromun further demonstrates potent activity in recurrent glioblastoma with durable major responses. Pivotal clinical trials in soft-tissue sarcoma and glioblastoma are on track. OncoFAP shows potent activity as a small molecule-drug conjugate. 177Lu-BiOncoFAP therapy shown to eradicate cancer in pre-clinical studies. Signed contract with Senn Chemicals for the GMP manufacturing of the product. [...]

Philochem and Bracco Imaging Announce a Collaboration on the Development of a Small Molecule for Diagnostic or Medical Imaging Applications

Siena, Italy, March 22 (Korea Bizwire) – Philochem, a subsidiary of the Philogen Group, and Bracco Imaging today announce that they have entered into a license and collaboration agreement to develop and commercialize a small organic molecule for imaging applications, with proven ability to selectively detect a variety of metastatic solid tumors in cancer patients, paving the way [...]

Philogen Announces Publication of PET Clinical Data with Proprietary Ultra-high Affinity FAP-targeting Small Molecule Ligand (OncoFAP)

Siena, Italy, Jan. 7 (Korea Bizwire) - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, announces that its wholly-owned Swiss subsidiary, Philochem AG, has co-authored a new translational study on 68Ga-OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation. The paper, entitled “Translational imaging of the fibroblast activation [...]

Philogen Announces New Collaboration with Janssen to Discover Small Molecules Therapeutics

Siena, Italy, Nov. 24 (Korea Bizwire) - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, today announces that its wholly-owned Swiss subsidiary, Philochem AG, has entered into a new collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecules [...]

Philogen Provides Corporate Update

Nidlegy™ and Fibromun are on track with planned timelines in pivotal clinical trials Fibromun shows potent activity in last-line glioblastoma in combination with Lomustine The OncoFAP platform shows promising results beyond radio-conjugates Cash & cash equivalents of €107.8M Philogen’s management team will hold a Webinar to discuss the news on November 12th, 2021, at 11:00 EST / 16:00 BST / 17:00 CEST (Please find the link to this [...]

Philogen Provides Corporate Update

Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trials Use of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical trials Early evidence of potent activity of Fibromun in combination with Standard of Care in last line patients with Glioblastoma and Soft Tissue Sarcoma Clinical experience with OncoFAP confirms preclinical results, recently published [...]

Philogen Announces R&D Program Update

Siena (Italy), July 2 (Korea Bizwire) – Philogen S.p.A. (BIT:PHIL), a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to provide an update on three R&D programs: Fibromun, OncoFAP and ABBV-022. A full pipeline update will be made to the market on 28 September, [...]

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

NidlegyTM on track for Phase III European trial in stage IIIB/C melanoma. Opening of additional clinical centers to boost recruitment rate is ongoing. Emerging promising data in non-melanoma skin cancers Fibromun on track for the six ongoing trials in Soft Tissue Sarcoma and High-Grade Glioma Philogen is well capitalized, with cash & cash equivalents of about € 120 million Philogen’s management team will hold a [...]